Prescription drug · NDA
Relenza (zanamivir) NDC 0173-0681
Zanamivir 5 mg/1 · Powder · Respiratory (Inhalation) · GlaxoSmithKline LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0173-0681-01 | 00173068101 | 5 PACKAGE in 1 CARTON (0173-0681-01) / 4 POWDER in 1 PACKAGEMarketed from Sep 22, 1999 | |
| 0173-0681-22 | 00173068122 | 5 PACKAGE in 1 CARTON (0173-0681-22) / 4 POWDER in 1 PACKAGEMarketed from Mar 9, 2007 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Relenza
- Generic name (nonproprietary)
- zanamivir
- Active ingredients
- Zanamivir — 5 mg/1
- Dosage form
- Powder
- Route
- Respiratory (Inhalation)
- Labeler
- GlaxoSmithKline LLC
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 021036
- Marketing start
- Listing expires
- Other FDA classes
- Neuraminidase Inhibitors (Mechanism)
- Identifiers
- Product ID 0173-0681_83f3d9aa-a169-487f-bd13-3199196b4801SPL ID 83f3d9aa-a169-487f-bd13-3199196b4801SPL set ID d7c3bcc3-0c0d-4068-fd80-88cf54a376efRxCUI 759471, 759473UNII L6O3XI777I
- Pharmacologic class
- Neuraminidase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N400173068101followed by a unit qualifier and the quantityPackage 00173-0681-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
RELENZA, an influenza virus neuraminidase inhibitor (NAI), is indicated for: Treatment of acute, uncomplicated influenza type A and B infections in patients aged 7 years and older who have been symptomatic for no more than 2 days. ( 1.1 ) Prophylaxis of influenza in patients aged 5 years and older. ( 1.2 ) Important Limitations of Use: Not recommended for treatment or prophylaxis of influenza in: • Individuals with underlying airways disease. ( 5.1 ) Not proven effective for: • Treatment in individuals with underlying airways disease. ( 1.3 ) • Prophylaxis in nursing home residents. ( 1.3 ) Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza…
Excerpt only. Read the full label for complete information.